SILVER SPRING, Md. -- The first drug shown to prevent HIV infection won the endorsement of a panel of federal advisers yesterday, clearing the way for a landmark approval in the 30-year fight against the virus that causes AIDS.

In a series of votes, a Food and Drug Administration advisory panel recommended approval of the daily pill Truvada for healthy people who are at high risk of contracting HIV, including gay and bisexual men and heterosexual couples with one HIV-positive partner.

The FDA is not required to follow the panel's advice, though it usually does. A final decision is expected by June 15.

Gilead Sciences Inc., based in Foster City, Calif., has marketed Truvada since 2004 as a treatment for people who are infected with the virus. The medication is a combination of two older HIV drugs, Emtriva and Viread. Doctors usually prescribe it as part of a drug cocktail to suppress the virus. -- AP

Yankees swept out of playoffs... Billy Joel's motorcycles on display at auction... New details in death of 7-year-old girl Credit: Newsday

Home healthcare wage thefts... Maduro indicted on new charges... Lead in LI school water

Yankees swept out of playoffs... Billy Joel's motorcycles on display at auction... New details in death of 7-year-old girl Credit: Newsday

Home healthcare wage thefts... Maduro indicted on new charges... Lead in LI school water

Subscribe

Unlimited Digital AccessOnly 25¢for 6 months

SUBSCRIBESALE ENDS SOON | CANCEL ANYTIME